Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03692312 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
A Phase 2 study, sponsored by AMO Pharma Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT03692312: Completed Phase 2 study, sponsored by AMO Pharma Limited.
NCT03692312 is a Phase 2 study that has completed, run by AMO Pharma Limited. The registered enrollment target is 56 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03692312, a Phase 2 study, has completed, sponsored by AMO Pharma Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of patients (aged 6 to 16 years) diagnosed with Congenital Myotonic Dystrophy (Congenital DM1).
Primary Outcome
The Clinician-Completed Congenital DM1 Scale is an 11-item rating scale completed by the clinician that scores the symptom severity of domains that are clinically relevant in Congenital DM1. The severity of the clinician's concern in each domain is scored by using a 5-point Likert Scale. Scores range from 0 = Not present to 4 = Very severe.
Interventions
- DRUG Placebo
- DRUG Tideglusib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-03-03 |
| Est. Completion | 2023-04-04 |
| Phase | Phase 2 |
What the finished NCT03692312 record still lists
NCT03692312 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03692312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03692312 about?
NCT03692312 is a clinical study titled "Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy". This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of patients (aged 6 to 16 years) diagnosed with Congenital Myotonic Dystrophy (Congenital DM1).
What is the current status of trial NCT03692312?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2021-03-03. Estimated completion is 2023-04-04.
What interventions are being tested in trial NCT03692312?
The interventions under investigation include: Placebo (DRUG), Tideglusib (DRUG).
Who is sponsoring clinical trial NCT03692312?
This trial is sponsored by AMO Pharma Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03692312's enrollment target sits among peer trials
56 1146th of 2000 higher than 848 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI